FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008751589> ?p ?o ?g. }

• W2008751589 abstract "Background The relationship between anticitrullinated protein antibodies (ACPA) and the clinical outcome of rheumatoid arthritis (RA) under treatment has been evaluated in clinical trials with conflicting results. Thus, an analysis of the BeSt study indicated that response to treatment was similar in ACPA-positive and ACPA-negative patients (van den Broek et al , Ann Reum Dis 2012; 71: 245–248). However, ACPA-positive patients showed more frequently radiological damage progression. On the contrary, in the IMPROVED study, ACPA-negative patients achieved less remissions on treatment than ACPA-positive patients (Wevers-de Boer et al , Ann Reum Dis 2012). Because of these, we evaluated the clinical response of patients with RA receiving treatment according to ACPA titers. Patients and Methods This was a retrospective longitudinal observational study. We included all patients seen at our Unit who fulfilled the following criteria: 1) Diagnosis of RA by a rheumatologist meeting the 1987 criteria for RA; 2) Available determinations of ACPA; 3) Treatment for AR (whether or not biological therapy) with a minimum follow up of 6 months. The outcome variable was clinical regression defined as reaching DAS28 ≤ 2.6. Predictors of the outcome variable were evaluated using logistic regression models adjusted by gender and age. Results 71 patients were included, 79% of them women. Clinical regression was observed in 42 (59%) patients during the first 12 months of follow-up. Baseline median (IQR) ACPA levels were 363 (27.7–500) for individuals without clinical regression and 91.7 (7–458) for those with regression (p = 0.045). 19 (66%) patients without regression versus 15 (36%) with regression showed ACPA levels ≥200 (p = 0.013). 6 (20%) patients without clinical response versus 18 (42%) individuals with response showed negative ACPA titers (p = 0.050). Factors independently associated with clinical regression were: Recent onset RA [adjusted odds ratio (AOR) 5; 95% confidence interval (95%CI) 1.01–25; p = 0.049], baseline ACPA levels ≥200 [AOR 0.13; 95%CI 0.03–0.5; p = 0.004], baseline CRP levels [per unit increase; AOR 0.94; 95%CI 0.91–0.99; p = 0.024], baseline DAS28 [per unit increase; AOR 0.47; 95%CI 0.25–0.89; p = 0.021]. Conclusions ACPA levels can predict clinical regression of patients with RA receiving treatment in real life conditions. Individuals with high ACPA levels may benefit from a more aggressive treatment approach. ACPA titers may be useful to monitor the clinical activity of RA." @default.
• W2008751589 created "2016-06-24" @default.
• W2008751589 creator A5006007376 @default.
• W2008751589 creator A5013229287 @default.
• W2008751589 creator A5061723881 @default.
• W2008751589 creator A5091235948 @default.
• W2008751589 date "2013-02-25" @default.
• W2008751589 modified "2023-09-24" @default.
• W2008751589 title "A1.9 Prediction of Treatment Response by ACPA Levels among Patients with Rheumatoid Arthritis" @default.
• W2008751589 doi "https://doi.org/10.1136/annrheumdis-2013-203214.9" @default.
• W2008751589 hasPublicationYear "2013" @default.
• W2008751589 type Work @default.
• W2008751589 sameAs 2008751589 @default.
• W2008751589 citedByCount "0" @default.
• W2008751589 crossrefType "journal-article" @default.
• W2008751589 hasAuthorship W2008751589A5006007376 @default.
• W2008751589 hasAuthorship W2008751589A5013229287 @default.
• W2008751589 hasAuthorship W2008751589A5061723881 @default.
• W2008751589 hasAuthorship W2008751589A5091235948 @default.
• W2008751589 hasBestOaLocation W20087515891 @default.
• W2008751589 hasConcept C126322002 @default.
• W2008751589 hasConcept C151956035 @default.
• W2008751589 hasConcept C167135981 @default.
• W2008751589 hasConcept C23131810 @default.
• W2008751589 hasConcept C2777575956 @default.
• W2008751589 hasConcept C535046627 @default.
• W2008751589 hasConcept C71924100 @default.
• W2008751589 hasConceptScore W2008751589C126322002 @default.
• W2008751589 hasConceptScore W2008751589C151956035 @default.
• W2008751589 hasConceptScore W2008751589C167135981 @default.
• W2008751589 hasConceptScore W2008751589C23131810 @default.
• W2008751589 hasConceptScore W2008751589C2777575956 @default.
• W2008751589 hasConceptScore W2008751589C535046627 @default.
• W2008751589 hasConceptScore W2008751589C71924100 @default.
• W2008751589 hasLocation W20087515891 @default.
• W2008751589 hasOpenAccess W2008751589 @default.
• W2008751589 hasPrimaryLocation W20087515891 @default.
• W2008751589 hasRelatedWork W1988125548 @default.
• W2008751589 hasRelatedWork W2019120227 @default.
• W2008751589 hasRelatedWork W2056013179 @default.
• W2008751589 hasRelatedWork W2127049275 @default.
• W2008751589 hasRelatedWork W2317799447 @default.
• W2008751589 hasRelatedWork W2319857254 @default.
• W2008751589 hasRelatedWork W2322163048 @default.
• W2008751589 hasRelatedWork W2324787549 @default.
• W2008751589 hasRelatedWork W2411299405 @default.
• W2008751589 hasRelatedWork W2551982449 @default.
• W2008751589 hasRelatedWork W2588332779 @default.
• W2008751589 hasRelatedWork W2754650263 @default.
• W2008751589 hasRelatedWork W2755067043 @default.
• W2008751589 hasRelatedWork W2755318883 @default.
• W2008751589 hasRelatedWork W2755403882 @default.
• W2008751589 hasRelatedWork W2908732520 @default.
• W2008751589 hasRelatedWork W2908736528 @default.
• W2008751589 hasRelatedWork W2951269605 @default.
• W2008751589 hasRelatedWork W3047667983 @default.
• W2008751589 hasRelatedWork W3164523844 @default.
• W2008751589 isParatext "false" @default.
• W2008751589 isRetracted "false" @default.
• W2008751589 magId "2008751589" @default.
• W2008751589 workType "article" @default.